Omeros has settled a patent infringement suit filed last year against Lupin for the filing of an abbreviated new drug application with the FDA for a generic version on Omeros’ Omidria, according to a press release.
Lupin will acknowledge and confirm the validity of all asserted patents for Omidria (phenylephrine 1% and ketorolac 0.3% intraocular solution), as well as overall terms and market entry date, the release said.
The last of Omeros’ Omidria patents will expire Oct. 23, 2033.
Omeros settled a similar suit against Par Sterile Products LLC and (Read more...)
Uncategorized